Skip to main content
OpenTrials
Completed

NCT Number: NCT04782076

A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants

The main purpose of this study is to determine the effect of selpercatinib on the levels of dabigatran in the blood stream and how long it takes the body to remove dabigatran. This study will also look at how safe and well-tolerated of dabigatran when administered in combination with selpercatinib in healthy participants. This study will last approximately 22 to 25 days.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Covance Clinical Research Inc

Daytona Beach, Florida, 32117, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Overtly healthy males or females, as determined by medical history, physical examination and vital signs.
  • Body mass index (BMI) within the range of 19 to 35 kilograms per meter squared (kg/m²)
  • Male participants are not required to adhere to contraceptive requirements and female participants of childbearing potential must agree to be either remain abstinent or stay in a same sex relationship without sexual relationships with males or must agree to use a highly effective method of contraception and who underwent bilateral salpingectomy. The Female participants not of childbearing potential are not required to use contraception.

Exclusion criteria

  • Have a positive pregnancy test at screening or Day -1, where applicable
  • Are planning to become pregnant during the study or within 1 month of study completion
  • Are women who are lactating
  • Have known allergies to selpercatinib- or dabigatran-related compounds or any components of the formulation of selpercatinib or dabigatran, or history of significant atopy
  • Have a history of allergic reactions to medications or food products
  • Have a clinically significant abnormality of blood pressure and/or pulse rate as determined by the investigator
  • Have known bleeding disorder including prior personal or familiar history of abnormal bleeding, hereditary or acquired coagulation or platelet disorder
  • Clinically significant abnormalities on ECG as determined by the investigator or prolongation of the QTcB or QTcF >450 msec on more than 1 ECG obtained during screening only
  • Have clinically significant active cardiovascular disease or history of myocardial infarction within 6 months prior to the planned start of selpercatinib
  • Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have an average weekly alcohol intake that exceeds 21 units per week (males ≤65 years old) and 14 units per week (females); 1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirit(s)
  • Are smokers of more than 10 cigarettes or e-cigarettes, or 3 cigars or 3 pipes, per day
  • Consume excessive amounts of coffee, tea, cola, or other caffeinated beverages per day

Treatment and study plan

dabigatran

Drug

Administered orally.

Selpercatinib

Drug

Administered orally.

Other names: LY3527723

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Dabigatran

    Time frame: Day 1 and Day 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hours (h) postdose

    PK: Cmax of Dabigatran

  2. PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of Dabigatran

    Time frame: Day 1 and Day 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 h postdose

    PK: AUC(0-inf) of Dabigatran

Secondary outcomes

  1. PK: Cmax of Selpercatinib

    Time frame: Day 8: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 h postdose

    PK: Cmax of Selpercatinib

  2. PK: AUC(0-inf) of Selpercatinib

    Time frame: Day 8: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 h postdose

    PK: AUC(0-inf) of Selpercatinib

  3. PK: Time of Maximum Observed Drug Concentration (Tmax) of Selpercatinib

    Time frame: Day 8: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 h postdose

    PK: Tmax of Selpercatinib

Sponsors and collaborators

Lead sponsor

Loxo Oncology, Inc.

Industry

Collaborators

  • Eli Lilly and Company

Registry information

Official study title

An Open-Label Study to Investigate the Effect of Selpercatinib on the Pharmacokinetics of Dabigatran in Healthy Volunteers

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Mar 4, 2021
Registry last updated
May 24, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.